当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.

The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.

Abstract：

BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving peg-IFN/RBV, the feasibility of predicting treatment failure using receiver operating characteristics (ROC) curves after measuring week 4 HCV RNA decreases, and to assess baseline predictors of not achieving sustained virological response (SVR). RESULTS:Peg-IFN-alpha2b was used in 84.5% of patients. Fifty-three (41%) reached SVR. The best cutoff value of HCV RNA decrease at week 4 to predict non-SVR corresponded to 1 log10 IU/ml: sensitivity and negative predictive value: 100%; specificity: 64%; positive predictive value: 66%; ROC curve area: 0.91 (95% confidence interval [CI]: 0.86-0.96). By applying this threshold, treatment could have been discontinued at week 4 in 64% of virological non-responders (49/76). By univariate analysis, baseline HCV RNA > 800,000 IU/ml (P = 0.029), older age (P = 0.011), and higher aspartate aminotransferase (AST) levels (P = 0.005) or AST/alanine aminotransferase ratio values (P = 0.04) were associated with failure. After multivariate analysis, only baseline HCV RNA >800,000 IU/ml (odds ratio [OR]: 2.12; 95% CI: 1.005-4.488; P = 0.048) and higher AST levels (OR: 1.01; 95% CI: 1.003-1.024; P = 0.011) remained statistically significant. CONCLUSIONS:The lack of > or = log10 IU/ml decrease in baseline HCV RNA at week 4 was 100% predictive of treatment failure, independently associated with HCV RNA > 800,000 IU/ml and higher AST levels.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Bárcena R,Moreno A,del Campo S,Muriel A,Mateos ML,Garrido E,García M,Quereda C,Moreno S,Moreno A

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

401-6

issue

3

eissn

1359-6535

issn

2040-2058

journal_volume

12

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

    abstract：BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2722

    authors： Gutierrez-Valencia A,Torres-Cornejo A,BenMarzouk-Hidalgo OJ,Ruiz-Valderas R,Lluch A,Viciana P,López-Cortés LF

    更新日期：2014-01-01 00:00:00

  • The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

    abstract：OBJECTIVES:Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We a...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Sternfeld T,Schmid M,Tischleder A,Mudra S,Schlamp A,Kost BP,Gruber R,Youle M,Bogner JR,Goebel FD

    更新日期：2007-01-01 00:00:00

  • Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

    abstract：OBJECTIVES:To characterize 1-year virological response to antiretroviral therapy and its determinants by sex. METHODS:This is a population-based analysis of antiretroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml w...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： O'Connell JM,Braitstein P,Hogg RS,Yip B,Craib KJ,O'Shaughnessy MV,Montaner JS,Burdge DR

    更新日期：2003-12-01 00:00:00

  • K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

    abstract：:Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe the surprising and consistent genotypic and phenotypic outcome in patients failing this combination. As part of a Da...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Røge BT,Katzenstein TL,Obel N,Nielsen H,Kirk O,Pedersen C,Mathiesen L,Lundgren J,Gerstoft J

    更新日期：2003-04-01 00:00:00

  • Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.

    abstract：BACKGROUND:Potential drug-drug interactions (PDDIs) might expand with new combination antiretroviral therapies (ART) and polypharmacy related to increasing age and comorbidities. We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability. METH...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1540

    authors： Marzolini C,Elzi L,Gibbons S,Weber R,Fux C,Furrer H,Chave JP,Cavassini M,Bernasconi E,Calmy A,Vernazza P,Khoo S,Ledergerber B,Back D,Battegay M,Swiss HIV Cohort Study.

    更新日期：2010-01-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract：INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1834

    authors： Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期：2011-01-01 00:00:00

  • Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy.

    abstract：BACKGROUND:Dyslipidaemia and lipodystrophy have been described in treated HIV patients and in a small percentage of untreated HIV patients. Lipodystrophy in these patients has been shown to be associated with a lower expression of low density lipoprotein (LDL) receptors. METHODS:We have investigated the effect of anti...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Umpleby AM,Das S,Stolinski M,Shojaee-Moradie F,Jackson NC,Jefferson W,Crabtree N,Nightingale P,Shahmanesh M

    更新日期：2005-01-01 00:00:00

  • Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.

    abstract：:We report the first two paediatric cases of sofosbuvir treatment during high-intensity myeloablative conditioning and engraftment phases of haematopoietic stem cell transplantation. These reports highlight the safety of sofosbuvir during all phases of transplantation and the lack of interaction between sofosbuvir and ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3332

    authors： Grasso AG,Sonzogni A,Zanon D,Maestro A,Loiacono S,Maximova N

    更新日期：2019-01-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract：:MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2766

    authors： van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期：2014-01-01 00:00:00

  • Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

    abstract：BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2570

    authors： Flores MV,Corbau RG,Guionaud S

    更新日期：2013-01-01 00:00:00

  • Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

    abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Laufer N,Laguno M,Perez I,Cifuentes C,Murillas J,Vidal F,Bonet L,Veloso S,Gatell JM,Mallolas J

    更新日期：2008-01-01 00:00:00

  • Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

    abstract：OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANR

    更新日期：2007-01-01 00:00:00

  • Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.

    abstract：BACKGROUND:Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV treatments often include dolutegravir, raltegravir, rilpivirine or cobicistat, which inhibit the prox...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3373

    authors： Brunet L,Wyatt C,Hsu R,Mounzer K,Fusco J,Fusco G

    更新日期：2020-11-19 00:00:00

  • A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.

    abstract：BACKGROUND:Lamivudine (3TC) therapy can cause the emergence of M1841/V. Previous studies suggest a higher fidelity of the mutant reverse transcriptase and lower replication capacity of the mutant virus. No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination a...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Fox Z,Dragsted UB,Gerstoft J,Phillips AN,Kjaer J,Mathiesen L,Youle M,Katlama C,Hill A,Bruun JN,Clumeck N,Dellamonica P,Lundgren JD,COLATE study group.

    更新日期：2006-01-01 00:00:00

  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract：OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期：2006-01-01 00:00:00

  • The potential role of HCV core antigen testing in diagnosing HCV infection.

    abstract：:The potential uses of serological tests that detect HCV core antigens in biological fluids are highlighted. The most common serological tests utilized to detect exposure to HCV rely on the detection of antibodies to HCV. However, these tests cannot distinguish between individuals who have resolved their infection and ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2463

    authors： Dawson GJ

    更新日期：2012-01-01 00:00:00

  • Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

    abstract：BACKGROUND:Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characte...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2749

    authors： Moholisa RR,Schomaker M,Kuhn L,Meredith S,Wiesner L,Coovadia A,Strehlau R,Martens L,Abrams EJ,Maartens G,McIlleron H

    更新日期：2014-01-01 00:00:00

  • Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

    abstract：BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3137

    authors： Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

    更新日期：2017-01-01 00:00:00

  • Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.

    abstract：BACKGROUND:The multidrug resistance proteins (MRPs) form a subfamily within the ATP binding cassette transporters that confer resistance to a variety of structurally unrelated compounds. MRP4 has been reported to transport antiretroviral drugs out of cells in an active process. Although the main therapeutic effects of ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1468

    authors： Clemente MI,Alvarez S,Serramía MJ,Turriziani O,Genebat M,Leal M,Fresno M,Muñoz-Fernández MA

    更新日期：2009-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期：2006-01-01 00:00:00

  • Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.

    abstract：BACKGROUND:In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complica...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1858

    authors： Ruiz-Camps I,Len O,de la Cámara R,Gurguí M,Martino R,Jarque I,Barrenetxea C,Díaz de Heredia C,Batlle M,Rovira M,de la Torre J,Torres A,Aguilar M,Espigado I,Martín-Dávila P,Bou G,Borrell N,Aguado JM,Pahissa A,Spanish

    更新日期：2011-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract：:Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Nolan D,John M,Mallal S

    更新日期：2001-09-01 00:00:00

  • Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

    abstract：BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3358

    authors： Bijker R,Kiertiburanakul S,Kumarasamy N,Pujari S,Sun LP,Ng OT,Lee MP,Choi JY,Nguyen KV,Chan YJ,Merati TP,Cuong DD,Ross J,Jiamsakul A,IeDEA Asia-Pacific.

    更新日期：2020-01-01 00:00:00

  • Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.

    abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3281

    authors： Bremer B,Anastasiou OE,Ciesek S,Wedemeyer H

    更新日期：2019-01-01 00:00:00

  • Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

    abstract：:Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP3245

    authors： Forton D,Weissenborn K,Bondin M,Cacoub P

    更新日期：2018-01-01 00:00:00

  • Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.

    abstract：:We investigated whether or not mutations at codon 215 in the HIV reverse-transcriptase-encoding gene predicted a lower efficacy of didanosine therapy, as defined by survival of patients and change in CD4 cell counts in 121 HIV-infected, zidovudine-experienced patients. A trend for shorter survival, although not reachi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yerly S,Denereaz N,Mermillod B,Hirschel B,Perrin L

    更新日期：1996-08-01 00:00:00

  • Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.

    abstract：BACKGROUND:IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV-HCV-coinf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2921

    authors： Neukam K,Munteanu D,Haubitz S,Mira JA,Ingiliz P,Rivero-Juárez A,Lutz T,de los Santos-Gil I,Scholten S,Márquez M,Rauch A,Rockstroh JK,Pineda JA

    更新日期：2015-01-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.

    abstract：BACKGROUND:A significant proportion of hepatitis C patients treated with unmodified interferon plus ribavirin fail to respond. The optimal therapy for these patients has not been established yet. The objective of this study was to assess the efficacy and safety of peginterferon plus ribavirin with or without amantidine...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Hasan F,Al-Khaldi J,Asker H,Al-Ajmi M,Owayed S,Varghese R,Siddique I,Al-Nakib B

    更新日期：2004-08-01 00:00:00

  • Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

    abstract：:There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these ag...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Wainberg MA,Sawyer JP,Montaner JS,Murphy RL,Kuritzkes DR,Raffi F

    更新日期：2005-01-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP1489

    authors： European Collaborative Study.

    更新日期：2010-01-01 00:00:00